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2005-2011 for new drugs and new indications for existing drugs were identified 
from the European Medicines Agency (EMA) website. The decision to undertake an 
appraisal was obtained from the NICE website and NIHR Horizon Scanning Centre 
records, and the associations between this and characteristics of the drug and 
intended patient population were then determined. Results: For 2005-2011, we 
identified 134 MAs granted by the EMA (116 new drugs and 18 new indications) of 
which 72 (54%) were selected for appraisal. The decision to undertake an appraisal 
was significantly associated with an MA granted 2009-2011 (OR= 2.3, p< 0.01), the 
drug being a biological agent (OR= 3.9, p< 0.01), administered on a long-term basis 
(OR= 1.8, p< 0.05), indicated for a patient population < 1 in 1,000 (OR= 2.1, p< 0.05), or 
for malignant disease (OR= 5.1, p< 0.01). It was not associated with an indication for 
more severe disease (OR= 2.0, p= 0.06), an MA issued for a new indication (OR= 1.4, 
p= 0.50), or whether a drug was first-of-kind (OR= 1.8, p= 0.10). ConClusions: We 
identified several characteristics associated with the decision to undertake an 
appraisal relating to both the drug and intended patient population that do not 
completely match published topic selection criteria (e.g. severity). Further analyses 
are required to determine which are the most relevant factors in this decision.
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objeCtives: Decision on the cost-effectiveness (CE) of health care technologies 
usually creates an argument especially when alternatives are more expensive but 
more effective. In this situation, external criterion in the form of CE threshold or 
willingness-to-pay for a quality-adjusted life-year (WTP/QALY) needs to be applied 
to decide on its CE. Nevertheless, the lack of empirical and well-accepted CE thresh-
old in Malaysia is recognized as one of the most important barriers in using health 
technology assessment for decision making. This study was mainly done to deter-
mine the CE threshold value across Malaysian population, estimated in terms of 
societal WTP for a QALY. Methods: A cross-sectional, contingent valuation study 
was conducted using stratified multistage cluster random sampling technique in the 
states of Penang, Kedah, Selangor and Kuala Lumpur Federal Territory. Respondents 
were asked for the socioeconomic background, quality of life and their WTP for a 
hypothetical EQ-5D health state scenario (treatment, extended life in terminal ill-
ness and life saving situations with three health severities – mild, moderate and 
severe, and two QALY gained levels – 0.2 QALY and 0.4 QALY) using pre-designed 
questionnaires. Interval model analysis was applied to determine the CE thresh-
old. Results: One thousand thirteen respondents aged between 20–60 years old 
who can understand either English or Malay language were interviewed face-to-
face. The mean value of CE threshold was determined at the range of MYR 19,929 to 
MYR 28,469 (~ USD 6,200 to USD 8,900). ConClusions: By comparing our results to 
Malaysian GDP per capita in the year 2013; ~ MYR 33,754 (~ USD 10,548), we noted 
that the mean WTP/QALY is ranged between 0.59–0.84 times of GDP per capita.
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objeCtives: The aim of this study is to review published economic evaluation of 
health technologies conducted in Brazil. Methods: Systematic review of economic 
evaluations studies published in MEDLINE, EMBASE, LILACS, SciELO, NHS EED, HTA 
Database, Web of Science, SCOPUS, BVS ECOS and SISREBRATS from 1980 to 2013. 
Full (Cost consequence analysis - CCA, cost minimization analysis - CMA, cost-
effectiveness analysis - CEA, cost-utility analysis - CUA, and cost-benefit analysis 
- CBA) and partial (cost description - CD and cost analysis - CA) economic evalua-
tion studies were eligible for inclusion if at least one of the authors was Brazilian 
and was affiliated to a Brazilian institution. Two independent reviewers screened 
articles for relevance and carried out data extraction. Disagreements were resolved 
through discussion or through consultation with a third reviewer. We performed a 
qualitative narrative synthesis. Results: We identified 11946 records and 557 met 
inclusion criteria. One hundred and ninety (34.1%) were full (of these, 56.6% CEA, 
20.3% CCA, 12.7% CUA, 5.6% CMA, and 4.7% CBA), and 367 were partial economic 
evaluation (of these, 64.7% CD and 32.3% CA). The main health problem studied were 
Infectious and Parasitic diseases (17.1%), Diseases of the Circulatory System (12.3%) 
and Neoplams (10.3%). The majority (72.9%) was conducted by authors from the 
southeast region, and south region (12.6%), mainly linked to academia (69.5%), and 
54.2% were published in medical and 18.9% in public health journals. Seventy-two 
(14.7%) studies reported to be funded by industry and 16% was considered to have 
conﬂict of interest. ConClusions: There was a considerable growth in the conduct 
and publication of economic evaluation studies in Brazil. A qualitative evaluation 
of the methodology used in those studies is important to legitimize their use in the 
process of local decision-making.
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objeCtives: Patient input is an important part of the assessment process, yet some-
times seen as having a low evidence base. Previous work by the authors shows more 
research is needed on identifying how the patient group contribution is impacting 
decision making. Our objective was to review and critically appraise existing pub-
lications on PAG involvement in HTA. Methods: A search in Pubmed, Cochrane 
and ISPOR databases since 2009 was undertaken to identify studies on patients 
or PAG involvement in the HTA decision. Studies were evaluated for relevancy. 
We extracted information on perceptions of patient input, process improvement 
recommendations, comparison of patient pathways and specific type of patient 
input desired. Two reviewers extracted methodological details, study designs, and 
outcomes into summary tables. Results: We identified 21 articles out of a total of 
18,829 studies. Articles covered multiple subject areas. Process improvements were 
most common (4 studies) followed by current perceptions (3 studies), comparison 
of patient pathways (2 studies) and specific type of patient input desired (1 study). 
Research methodologies and stakeholders varied widely including telephone, web 
audit, interview /questionnaire and literature review. Stakeholders varied between 
national & international HTA agencies, experts and patient groups. Three studies 
involved patient groups and one involved patients. These studies informed the role, 
process and nature of input but did not address the impact on HTA decision mak-
ing. ConClusions: Compared to other HTA areas there is a lack of published mate-
rial on PAG involvement. There have been many attempts to provide a framework 
for patient involvement but so far none has been used in HTA decision-making. 
Existing data does not help to quantify role of the patient in HTA decision making. 
Additional research is needed to understand and quantify patient group input in 
HTA decisions.
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objeCtives: Access to orphan drugs is often inconsistent, and is hindered by dif-
ficulties in demonstrating value in HTA appraisals due to the small patient popula-
tions and insufficient data. To inform future submissions, we examined the trends 
and key decision drivers that resulted in a submission being rejected across five HTA 
agencies. Methods:  The Orphanet database was searched for orphan drugs with a 
marketing authorisation between 2002 and 2014. To assume a certain level of com-
petition, awareness and commercial potential, rare diseases for which two or more 
orphan drugs were available were selected. Decisions from five HTA agencies were 
considered: AWMSG (Wales), CADTH (Canada), NICE (England), PBAC (Australia), 
and SMC (Scotland). Assessments that resulted in a rejection were examined for 
key decision drivers, and for trends and variation by disease type. Results: A total 
of 28 licensed orphan drugs were available for the treatment of eight rare diseases. 
The number of orphan drugs assessed, and rejection rates, varied by HTA agency; 
PBAC and SMC had the lowest rejection rates (4/18; 22% and 6/22; 27%, respectively), 
while NICE had the highest rejection rate with 40% (4/10). Uncertainties regarding 
clinical efficacy, and concerns over the robustness of economic evidence were the 
key decision drivers that led to a rejection. Examination of data by disease type 
indicated a trend towards higher rejection rates for diseases with a higher preva-
lence rate. ConClusions: The proportion of rejected submissions varied by HTA 
agency, particularly within the HTA bodies in the UK, highlighting inconsistencies 
in decision-making. An association between prevalence rate and the proportion of 
rejected submissions was found, with lower rates of disease prevalence correlating 
with higher acceptance rates. This is most likely due to the lower budget impact 
incurred in smaller patient populations.
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objeCtives: G-BA, IQWiG and GKV are the main governmental stakeholders in 
the German AMNOG process. Based on manufacturer-submitted dossiers, the G-BA 
assesses the drugs’ additional benefit per pre-defined subgroup. Subsequently, the 
GKV negotiates rebates by drug. This research aims to describe factors influenc-
ing GB-A decisions and assess the association between additional benefit and 
rebate. Methods: All G-BA decisions up to March 2014 were analyzed. Univariate 
logistic regression was used to investigate the relationship of G-BA decisions 
(dependent variable: additional benefit (y/n) per subgroup) with study character-
istics. Study characteristics included were disease area (ATC-code), superiority/
non-inferiority study design, comparators used in the submitted trials (in/direct; 
in/adequate comparator according to GBA [“ZVT”]), main area of claimed benefit 
e.g. overall survival (OS). Linear regression was used to assess the impact of added 
benefit (in at least one subgroup) on rebate. Results: Sixty-eight G-BA decisions, 
with in total 137 G-BA subgroups, were included and analyzed. In total, 60.3% of 
assessments resulted in an additional benefit. Most commonly, dossiers were sub-
mitted to the G-BA for ATC-codes L and A (39.7%; 19.1%). Out of 40 ATC-code L sub-
groups (27 drugs), 70.0% resulted in a positive assessment, with 50% demonstrating 
a benefit in OS. Univariate logistic regression showed a significant relationship 
between added benefit and: ATC-codes A/J/L; improvements in morbidity; adverse 
events; direct comparators; and the ZVT (ORs: 0.1; 11.2; 6.0; 55.2; 24.3; 20.9; 15.2; all 
p< 0.05). All drugs showing an OS advantage received a positive benefit assessment. 
Added benefit reduced the rebate significantly by 13.1% (p< 0.05). ConClusions: 
Key factors for a positive G-BA benefit assessment are improved OS, morbidity, and 
adverse events, demonstrated through the use of direct “ZVT” comparators. ATC-
codes J and L carry the highest chance of gaining a positive assessment. The rebate 
negotiated with the GKV decreases significantly if an added benefit is determined.
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objeCtives: To determine how often NICE recommendations are more restrictive 
than the market authorizations. Methods: 161 NICE Technology Appraisal deci-
sions from 2007-2013 were evaluated. These reviews included 80 unique drugs from 
37 disease conditions. For each generic drug included in a review, the corresponding 
